Insider Selling: Omnicell (NASDAQ:OMCL) EVP Sells $256,879.45 in Stock

Omnicell, Inc. (NASDAQ:OMCL) EVP Corey Manley sold 7,405 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $34.69, for a total value of $256,879.45. Following the completion of the sale, the executive vice president directly owned 96,717 shares in the company, valued at approximately $3,355,112.73. This trade represents a 7.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Omnicell Price Performance

Shares of OMCL opened at $33.40 on Friday. The company has a market cap of $1.52 billion, a P/E ratio of 835.21, a PEG ratio of 1.22 and a beta of 0.79. The stock has a fifty day moving average price of $42.66 and a 200 day moving average price of $38.46. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.43 and a quick ratio of 1.22. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.00.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The company had revenue of $313.98 million during the quarter, compared to the consensus estimate of $313.36 million. During the same quarter in the previous year, the business posted $0.60 earnings per share. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. On average, research analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on OMCL. UBS Group set a $60.00 target price on shares of Omnicell and gave the company a “buy” rating in a research note on Friday, March 13th. Wall Street Zen lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Benchmark reaffirmed a “buy” rating on shares of Omnicell in a report on Friday, March 13th. Piper Sandler reiterated an “overweight” rating and set a $49.00 price objective (down from $63.00) on shares of Omnicell in a research report on Friday, February 6th. Finally, KeyCorp raised Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective for the company in a report on Wednesday, January 7th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $58.50.

Institutional Investors Weigh In On Omnicell

A number of institutional investors and hedge funds have recently modified their holdings of OMCL. Dimensional Fund Advisors LP boosted its stake in shares of Omnicell by 9.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock worth $71,985,000 after acquiring an additional 197,462 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Omnicell by 156.4% during the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after purchasing an additional 1,265,818 shares during the period. Lazard Asset Management LLC lifted its holdings in shares of Omnicell by 3.8% during the second quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after purchasing an additional 62,733 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Omnicell by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,195,896 shares of the company’s stock valued at $35,163,000 after purchasing an additional 30,678 shares during the period. Finally, Millennium Management LLC acquired a new position in shares of Omnicell in the 3rd quarter valued at $25,625,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.